ReNeuron Group (RENE) ... a little gene therapy ??
Here's something for you punters and long haulers.
From TV: ..... ReNeuron Group Plc engages in the development of novel cell based therapies that target significant areas of unmet medical need. It develops its core stem cell assets such as CTX neural cell line and human retinal progenitor cells. The company was founded by John David Sinden in 1997 and is headquartered in Pencoed, the United Kingdom.
RENE last 92% of it value from the fall of 2019 and has clawed some of that back in recent weeks.
RENE trades on the LSE and the OTC but ususally by appointment.
Apparently the analysts love it. (that scares me sometimes)
This may have a chance if the high of February is taken out.
The chart suggest is a fairly good Harmonic Butterfly pattern on this weekly image.
Targets and a Stop have been marked, suggesting a RR of just over 2.5x .
I am mentioning but probably not playing. ( depends on broader market sentiment and Biotechs in particular.)
This company presently does not turn a profit. Earnings reports are expected mid July.
Not investment advice. As always do your own due diligence, respect broader market and wold events.
Good luck
S.
From TV: ..... ReNeuron Group Plc engages in the development of novel cell based therapies that target significant areas of unmet medical need. It develops its core stem cell assets such as CTX neural cell line and human retinal progenitor cells. The company was founded by John David Sinden in 1997 and is headquartered in Pencoed, the United Kingdom.
RENE last 92% of it value from the fall of 2019 and has clawed some of that back in recent weeks.
RENE trades on the LSE and the OTC but ususally by appointment.
Apparently the analysts love it. (that scares me sometimes)
This may have a chance if the high of February is taken out.
The chart suggest is a fairly good Harmonic Butterfly pattern on this weekly image.
Targets and a Stop have been marked, suggesting a RR of just over 2.5x .
I am mentioning but probably not playing. ( depends on broader market sentiment and Biotechs in particular.)
This company presently does not turn a profit. Earnings reports are expected mid July.
Not investment advice. As always do your own due diligence, respect broader market and wold events.
Good luck
S.
Comment:
Nothing yet... this is a long term view.